Abstract:A comprehensive summary of recent advances in SARS‐CoV‐2 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives), including the inhibitory activities, inhibitory mechanisms, and key structural features, provides new insights for designing and developing more efficacious 3CLpro inhibitors as broad‐spectrum anti‐coronavirus agents. The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CLpros play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus‐caused infectious diseases, including COVID‐19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) main protease Mpro (also known as 3CLpro), as well as recent advances in discovering and developing SARS‐CoV‐2 3CLpro inhibitors. To better understand the characteristics of SARS‐CoV‐2 3CLpro inhibitors, the inhibition activities, inhibitory mechanisms, and key structural features of various 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives) are summarized comprehensively. Meanwhile, the challenges in this field are highlighted, while future directions for designing and developing efficacious 3CLpro inhibitors as novel anti‐coronavirus therapies are also proposed. Collectively, all information and knowledge presented here are very helpful for understanding the structural features and inhibitory mechanisms of SARS‐CoV‐2 3CLpro inhibitors, which offers new insights or inspiration to medicinal chemists for designing and developing more efficacious 3CLpro inhibitors as novel anti‐coronavirus agents.

Transarterial Embolization of Cerebrospinal Lesions with Liquid Coils

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

A Secure and Efficient (t, n) Threshold Verifiable Multi-secret Sharing Scheme

Structural and mechanistic insights into Main protease (Mpro) dimer interface destabilization inhibitor: Unveiling new therapeutic avenues against SARS-CoV-2

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

Identification of SARS-CoV-2 Main Protease Inhibitors Using Chemical Similarity Analysis Combined with Machine Learning

Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814.

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Progress of SARS‐CoV‐2 Main Protease Peptide‐like Inhibitors

Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor

The S1′–S3′ Pocket of the SARS‐CoV‐2 Main Protease is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors

In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)

Design of novel and highly selective SARS-CoV-2 main protease inhibitors

First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery

Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

Progress of SARS-CoV-2 Main protease peptide-like inhibitors

Motility after abdominal surgery.